Last reviewed · How we verify

Levobupivacaine wound infiltration

University of Genova · FDA-approved active Small molecule

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Levobupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local anesthesia and analgesia for wound infiltration during surgical procedures.

At a glance

Generic nameLevobupivacaine wound infiltration
SponsorUniversity of Genova
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Levobupivacaine is the S-enantiomer of bupivacaine, a long-acting amide local anesthetic. It works by reversibly inhibiting sodium influx through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and action potential propagation. When infiltrated into wound tissue, it provides local anesthesia and analgesia by blocking sensory and motor nerve conduction in the infiltrated area.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: